title: Neoadjuvant chemotherapy: a new criterion for selection of candidate patients for surgery of low tumour burden metastases from malignant melanoma?
abstract: BACKGROUND
  Surgery of limited metastatic lesions from malignant melanoma can achieve long-term remission and better survival than chemotherapy. Existing criteria for selection of candidate patients for this surgery do not seem sufficient to avoid useless excisions.
  
  
  OBJECTIVE
  To test use of neoadjuvant chemotherapy as a new criterion in this setting.
  
  
  METHODS
  All patients who underwent thoracic surgery for one or two lung metastases from melanoma during 1999-2007 were included in the study. Demographic and medical data were collected and analysed. Several possible prognostic factors were evaluated based on the overall survival curves.
  
  
  RESULTS
  Thirteen patients were included in this retrospective study. All but two patients had no evidence of disease after surgery. Ten patients received neoadjuvant chemotherapy. Six responded (absence of progression) and four had progressive disease. Response to chemotherapy and no evidence of disease after surgery were predictive of long-term survival.
  
  
  CONCLUSIONS
  Neoadjuvant chemotherapy can be considered as a new criterion for better selection of candidate patients for lung metastasis surgical resection. This would also avoid useless surgical procedures in rapidly progressive disease and give information on the chemosensibility of the metastatic disease. This study needs further confirmation, particularly with chemotherapy regimens that have demonstrated better objective responses.
authors.affiliation: Skin Cancer Unit, Department of Dermatology, Saint André's Hospital, 1 Rue Jean Burguet, 33075 Bordeaux Cedex, France. thomas.jouary@chu-bordeaux.fr
authors.forename: T
authors.initials: T
authors.lastname: Jouary
authors.forename: C
authors.initials: C
authors.lastname: Legros
authors.forename: N
authors.initials: N
authors.lastname: Lalanne
authors.forename: J
authors.initials: J
authors.lastname: Versapuech
authors.forename: K
authors.initials: K
authors.lastname: Ezzedine
authors.forename: B
authors.initials: B
authors.lastname: Vergier
authors.forename: M
authors.initials: M
authors.lastname: Delaunay
authors.forename: J F
authors.initials: JF
authors.lastname: Velly
authors.forename: A
authors.initials: A
authors.lastname: Taieb
mesh_terms: D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant / Q000379:methods; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000601:surgery*; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary / Q000601:surgery*; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D018579:Patient Selection; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome